Twist Bioscience Corporation reports developments in synthetic biology built around its silicon-based DNA synthesis platform. Company updates cover synthetic DNA tools and services for diagnostics, therapeutics, industrial, agriculture and research markets, including oligos, genes, proteins, libraries, characterization data, antibody discovery solutions and NGS workflow tools.
Recurring announcements include fiscal results, business updates, product launches such as expanded clonal gene capabilities and library preparation kits, antibody discovery licensing, investor presentations and Nasdaq inducement equity awards for new employees.
Twist Bioscience (NASDAQ: TWST), a biotechnology company specializing in synthetic DNA, has announced its executives' participation in several upcoming investor conferences. Patrick Finn, Ph.D., president and COO, will join a fireside chat at the Leerink Partners Healthcare Crossroads Conference on May 29 in Austin, TX. Emily Leproust, Ph.D., CEO and co-founder, will present at the William Blair Growth Stock Conference on June 4 in Chicago, IL, at the Jefferies Global Healthcare Conference on June 6 in New York, NY, and will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11 in Miami, FL. The sessions will be webcast live and available on the company's website, with replays accessible for 30 days after the events.
Twist Bioscience (TWST) has launched Twist Multiplexed Gene Fragments (MGFs), pools of directly synthesized double-stranded DNA up to 500 base pairs in length, with no limit on sequence number, enabling high-throughput screening applications. This offering allows for rapid screening of diverse targets for CRISPR and genome engineering, antibody discovery, protein engineering, and more. The customizable fragments have a quick turnaround time, starting at 8 business days, making them versatile for various applications.
Twist Bioscience announced the granting of 87,200 restricted stock units to 26 new employees as inducement for joining the company. The RSUs vest over a 48-month period for each employee, with 25% vesting on the one year anniversary of employment and 1/16 vesting quarterly thereafter.
Twist Bioscience (NASDAQ: TWST) reported a record revenue of $75.3M in the second quarter of fiscal 2024, showing a 25% increase over the same period in fiscal 2023. Orders also grew by 45% to $93.2M. The company increased its revenue guidance for fiscal 2024 to a range of $300M to $304M and its gross margin guidance to 41.5% to 42.0%. Twist Bioscience continues to focus on profitability and aims to improve gross margin to over 50% by the end of fiscal 2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.